-
Article
Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes
-
Article
Open AccessThe ABNL-MARRO 001 study: a phase 1–2 study of randomly allocated active myeloid target compound combinations in MDS/MPN overlap syndromes
Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) comprise several rare hematologic malignancies with shared concomitant dysplastic and proliferative clinicopathologic features of bone marrow failure and ...
-
Article
Open AccessPhase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms
We conducted a phase I clinical trial of H3B-8800, an oral small molecule that binds Splicing Factor 3B1 (SF3B1), in patients with MDS, CMML, or AML. Among 84 enrolled patients (42 MDS, 4 CMML and 38 AML), 62 ...
-
Article
Author Correction: Blockade of IL-22 signaling reverses erythroid dysfunction in stress-induced anemias
-
Article
Author Correction: Fit older adults with advanced myelodysplastic syndromes: who is most likely to benefit from transplant?
A minor correction to the legend in a figure in this paper has been published and can be accessed via a link at the top of the paper.
-
Article
Fit older adults with advanced myelodysplastic syndromes: who is most likely to benefit from transplant?
We conducted a prospective observational study of fit adults aged 60–75 with advanced MDS, enrolled hierarchically for adverse MDS risk (intermediate-2 or high-risk international prognostic score [IPSS], low o...
-
Article
Blockade of IL-22 signaling reverses erythroid dysfunction in stress-induced anemias
Patients with myelodysplastic syndromes (MDSs) display severe anemia but the mechanisms underlying this phenotype are incompletely understood. Right open-reading-frame kinase 2 (RIOK2) encodes a protein kinase lo...
-
Article
Open AccessClonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant
Multiple myeloma (MM) is a plasma-cell neoplasm that is treated with high-dose chemotherapy, autologous stem cell transplant (ASCT) and long-term immunomodulatory drug (IMiD) maintenance. The presence of somat...
-
Article
Bone marrow niches in haematological malignancies
Haematological malignancies were previously thought to be driven solely by genetic or epigenetic lesions within haematopoietic cells. However, the niches that maintain and regulate daily production of blood an...
-
Article
The Clinical Challenge of Idiopathic Cytopenias of Undetermined Significance (ICUS) and Clonal Cytopenias of Undetermined Significance (CCUS)
To review terminology, diagnostic algorithms, and clinical outcomes for patients with unexplained blood cytopenias.
-
Article
Quality of life and mood of older patients with acute myeloid leukemia (AML) receiving intensive and non-intensive chemotherapy
Older patients with AML face difficult treatment decisions as they can be treated either with ‘intensive’ chemotherapy requiring prolonged hospitalization, or ‘non-intensive’ chemotherapy. Although clinicians ...
-
Article
Rethinking clinical trial endpoints in myelodysplastic syndromes
The myelodysplastic syndromes (MDS) are a heterogeneous collection of clonal, hematopoietic disorders primarily affecting an older population, making successful drug development a complicated process. A sole f...
-
Article
Uncoupling of CD71 shedding with mitochondrial clearance in reticulocytes in a subset of myelodysplastic syndromes
Reticulocytes shed CD71 from the cell membrane and eliminate mitochondria during terminal maturation, but it is unknown whether these two events are coordinated. We demonstrate that timely removal of CD71 is c...
-
Article
Open AccessMyelodysplastic syndromes current treatment algorithm 2018
Myelodysplastic syndromes (MDS) include a group of clonal myeloid neoplasms characterized by cytopenias due to ineffective hematopoiesis, abnormal blood and marrow cell morphology, and a risk of clonal evoluti...
-
Article
The bone-marrow niche in MDS and MGUS: implications for AML and MM
Multiple myeloma is almost always preceded by monoclonal gammopathy of undetermined significance, and at least one-quarter of all patients with myelodysplastic...
-
Article
Open AccessValidation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care
-
Article
The importance of erythroblast enumeration in myeloid neoplasia
-
Article
Targeting Splicing in the Treatment of Myelodysplastic Syndromes and Other Myeloid Neoplasms
Genome sequencing of primary cells from patients with myelodysplastic syndromes (MDS) led to the identification of recurrent heterozygous mutations in gene encoding components of the spliceosome, the cellular ...
-
Article
Open AccessConnect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study
Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are myeloid neoplasms in which outgrowth of neoplastic clones disrupts normal hematopoiesis. Some patients with unexplained persistent cytopenia...
-
Article
Clinical response to ruxolitinib in CSF3R T618-mutated chronic neutrophilic leukemia
